Business Wire

Foundation Medicine Expands Monitoring Portfolio with Launch of FoundationOne®Monitor

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc., today announced the launch of its tissue-naïve circulating tumor DNA (ctDNA) monitoring assay, FoundationOne®Monitor, for research use in ...
Business Wire

Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent Genetics

BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced plans to launch two new germline tests, ...
Morningstar

Foundation Medicine to Present Over 15 Abstracts at the 2025 ASCO® Annual Meeting

Foundation Medicine, Inc., a genomic company committed to transforming cancer care, today announced that the company and its collaborators will present more than 15 abstracts demonstrating the value ...
Nasdaq

Prime Medicine Secures Up to $24 Million from Cystic Fibrosis Foundation to Advance Prime Editing Technology for Cystic Fibrosis Treatment

Prime Medicine secures up to $24 million from the CF Foundation to advance Prime Editors for cystic fibrosis treatment. Prime Medicine, Inc. has announced an agreement with the Cystic Fibrosis ...